FluxMPS™ Minimum Essential Medium (MEM), Low Glucose w/o L-Glutamine, Sodium Pyruvate: 1X Liquid

FluxMPS™ Minimum Essential Medium (MEM), Low Glucose w/o L-Glutamine, Sodium Pyruvate: 1X Liquid

FluxMPS™ Minimum Essential Medium (MEM), Low Glucose w/o L-Glutamine, Sodium Pyruvate: 1X Liquid is a Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) 1X liquid cell culture medium engineered for microfluidic channels, organ-on-a-chip (OoC), tissue-on-a-chip (ToC), and microphysiological system (MPS) applications. The low-glucose, L-glutamine-free MEM base retains 110 mg/L sodium pyruvate and is buffered with sodium bicarbonate for standard 5% CO₂ culture, reaching a 0.04 µm final polish that conventional 0.22 µm-filtered media cannot match.

• Quadruple-stage filtration train: 0.1 µm → 0.04 µm → 0.1 µm → 0.04 µm, reaching a 0.04 µm final polish for microfluidic and organ-on-a-chip perfusion
• Low-glucose MEM base (1000 mg/L D-Glucose) formulated without L-Glutamine — supplement per your cell line's requirement
• Contains 110 mg/L sodium pyruvate as a supplemental carbon/energy source
• Sodium bicarbonate buffered (2200 mg/L NaHCO₃) for standard 5% CO₂ incubation, consistent with the formulation's pH 7.4
• Endotoxin release specification: < 0.05 EU/mL (LAL assay, USP <85> Bacterial Endotoxins Test), tested per manufacturing batch
• Manufactured under an ISO 13485:2016 quality management system, with final fill and release testing at Diagnocine, Totowa, NJ
• Custom pH, glucose, salts, HEPES, and nutrient composition available on request

Engineered where standard media fails

Conventional 0.22 µm-filtered media can carry mycoplasma-sized particulates (0.2–0.3 µm), subvisible debris, and endotoxin variability that accumulate inside microchannels — a common source of biosensor drift, culture stress, and shortened device lifetimes. FluxMPS™ is designed to address these failure modes through validated multi-stage filtration.

Quadruple-stage filtration system

FluxMPS™ Minimum Essential Medium (MEM), Low Glucose w/o L-Glutamine, Sodium Pyruvate: 1X Liquid is processed through a validated four-stage filtration train reaching a 0.04 µm final polish. Two dedicated 0.1 µm prefilter + 0.04 µm final-filter pairs run in series, giving redundant protection against particulate and mycoplasma-sized contaminants that pass a standard 0.22 µm filter.

1. 1

   0.1 µm Prefiltration I

   Removes large particulates, cell debris, and protein aggregates; protects the first 0.04 µm final filter cartridge.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and mycoplasma-sized material (0.2–0.3 µm) that a 0.22 µm filter does not.

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter, protecting the second 0.04 µm final filter cartridge from residual particulate load.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter; aseptic fill & finish in a validated ISO Class 5 laminar-flow workstation.

Designed for next-generation cell culture platforms

FluxMPS™ Minimum Essential Medium (MEM), Low Glucose w/o L-Glutamine, Sodium Pyruvate: 1X Liquid is suited for organ-on-a-chip, metabolic-flux research, live-cell imaging, and primary/vascular cell models where particulate load and endotoxin variability matter.

Automated Bioreactors & Robotics

An optional MPS Grade 0.01 µm (10 nm) ultra nano-filtered variant is available for automated bioreactor and robotic perfusion systems requiring the ultimate particulate exclusion — see the Grade note in the Purity Architecture section above for how this tier differs from the Microfluidics Suitable (0.04 µm) product on this page.

• Total Particulate Exclusion: 10 nm filtration for nanoscale valve and sensor protection
• Valve & Sensor Protection: prevents particulate-induced blockage in precision fluidic systems
• Extended Perfusion Stability: maintains flow rate consistency across multi-week automated runs

Inquiry Required: Contact support@diagnocine.com to request the MPS Grade 0.01 µm variant.

Lot-release quality parameters

Every production lot of FluxMPS™ Minimum Essential Medium (MEM), Low Glucose w/o L-Glutamine, Sodium Pyruvate: 1X Liquid undergoes the quality-release battery below before shipment.

Full composition (mg/L)

Complete formulation with CAS numbers, reproduced from manufacturer specification. Total: 29 components across 4 categories. Custom compositions available on request.

ISO 13485:2016 manufacturing & compliance

Manufactured under ISO 13485:2016 QMS with final packaging, testing, and customization at Diagnocine Precision in Totowa, New Jersey, USA.

How DCP-MEM-QPN1X (FluxMPS™) compares

Side-by-side comparison against conventional 0.22 µm-filtered alternatives of the same base formulation.

Comparison figures from published supplier specifications, accessed 2 September 2026. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ Minimum Essential Medium (MEM), Low Glucose w/o L-Glutamine, Sodium Pyruvate: 1X Liquid and Microfluidics Suitable cell culture media.

Supporting literature

Peer-reviewed publications supporting ultra-filtered media and microfluidic cell culture applications.

1. Huh D et al. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662–1668. doi:10.1126/science.1188302
2. Bhatia SN & Ingber DE (2014). Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760–772. doi:10.1038/nbt.2989
3. Eagle H (1959). Amino acid metabolism in mammalian cell cultures. Science, 130(3373), 432–437. doi:10.1126/science.130.3373.432
4. Bhattacharya S et al. (2018). Challenges in maintaining cell viability during microfluidic experiments. Electrophoresis, 39(7), 997–1006. doi:10.1002/elps.201700375
5. Zhang YS et al. (2017). Multisensor-integrated organs-on-chips platform for automated in situ monitoring. PNAS, 114(12), E2293–E2302. doi:10.1073/pnas.1612906114
6. Vernetti L et al. (2017). Functional coupling of human microphysiology systems. Scientific Reports, 7, 42296. doi:10.1038/srep42296
7. Esch EW et al. (2015). Organs-on-chips at the frontiers of drug discovery. Nature Reviews Drug Discovery, 14(4), 248–260. doi:10.1038/nrd4539
8. Zheng F et al. (2021). Organ-on-a-chip systems: microengineering to biomimic living systems. Small, 17(7), 2004175. doi:10.1002/smll.202004175